Real-world Efficacy and Safety of Stapokibart in Children and Adolescents with Moderate-to-severe Atopic Dermatitis: A Retrospective Study
Paediatric real-world evidence for stapokibart in moderate-to-severe atopic dermatitis (AD) is scarce. We retrospectively analysed 55 patients aged 6–17 years treated at a single centre for 16 weeks using weight-tiered dosing (<30 kg: 600 mg loading, then 300 mg every 4 weeks; ≥30 kg: 600 mg loadin...
保存先:
| 主要な著者: | , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Medical Journals Sweden
2026-05-01
|
| シリーズ: | Acta Dermato-Venereologica |
| 主題: | |
| オンライン･アクセス: | https://medicaljournalssweden.se/actadv/article/view/46103 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|